Geneva, Switzerland

Xavier Philippe Perret

This inventor holds 1 USPTO granted patent. Top assignee: Andre Rosenthal. Active years: 2002.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Xavier Philippe Perret

Introduction

Xavier Philippe Perret is a notable inventor based in Geneva, Switzerland. He has made significant contributions to the field of genomics, particularly through his work on the symbiotic plasmid of Rhizobium sp. NGR 234. His innovative research has implications for understanding plant-microbe interactions.

Latest Patents

Xavier Philippe Perret holds a patent for the genomic sequence of Rhizobium sp. NGR 234 symbiotic plasmid. This patent details the sequencing and analysis of the complete nucleotide sequence of the symbiotic plasmid pNGR234a, which was isolated from Rhizobium sp. NGR234. The complete sequence of pNGR234a is presented, along with the identification of several novel open reading frames (ORFs) and the proteins expressible therefrom, which have been ascribed putative functions. He has 1 patent to his name.

Career Highlights

Xavier Philippe Perret is associated with the company Andre Rosenthal, where he continues to advance his research in genomics. His work has garnered attention for its potential applications in agriculture and biotechnology.

Collaborations

Some of his notable coworkers include André Rosenthal and Christoph Freiberg. Their collaborative efforts contribute to the innovative research environment in which Perret operates.

Conclusion

Xavier Philippe Perret's contributions to the field of genomics through his patent on Rhizobium sp. NGR 234 symbiotic plasmid highlight his role as an influential inventor. His work continues to pave the way for advancements in understanding plant-microbe interactions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…